Ultrahypofractionated radiotherapy for localized prostate cancer with simultaneous boost to the dominant intraprostatic lesion: a plan comparison.


Journal

Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 27 4 2021
medline: 3 6 2022
entrez: 26 4 2021
Statut: ppublish

Résumé

To compare different stereotactic body techniques-intensity-modulated radiotherapy with photons and protons, applied to radiotherapy of prostatic cancer-with simultaneous integrated boost (SIB) on the dominant intraprostatic lesion (DIL). Ten patients were selected for this planning study. Dosimetric results were compared between volumetric modulated arc therapy, intensity-modulated radiation therapy (IMRT), and intensity-modulated proton therapy both with two (IMPT 2F) and five fields (IMPT 5F) planning while applying the prescription schemes of 7.25 Gy/fraction to the prostate gland and 7.5 Gy/fraction to the DIL in 5 fractions. Comparison of the coverages of the planning target volumes showed that small differences exist. The IMPT-2F-5F techniques allowed higher doses in the targets; conformal indexes resulted similar; homogeneity was better in the photon techniques (2%-5%). Regarding the organs at risk, all the techniques were able to maintain the dose well below the prescribed constraints: in the rectum, the IMPT-2F-5F and IMRT were more efficient in lowering the intermediate doses; in the bladder, the median dose was significantly better in the case of IMPT (2F-5F). In the urethra, the best sparing was achieved only by IMPT-5F. Stereotactic radiotherapy with SIB for localized prostate cancer is feasible with all the investigated techniques. Concerning IMPT, the two-beam technique does not seem to have a greater advantage compared to the standard techniques; the 5-beam technique seems more promising also accounting for the range uncertainty.

Identifiants

pubmed: 33896239
doi: 10.1177/03008916211011667
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-269

Auteurs

Raffaella Cambria (R)

Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Delia Ciardo (D)

Department of Radiation Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Alessia Bazani (A)

Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Floriana Pansini (F)

Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Elena Rondi (E)

Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Davide Maestri (D)

Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Dario Zerini (D)

Department of Radiation Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Giulia Marvaso (G)

Department of Radiation Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, via Festa del Perdono, Milan, Italy.

Pola Romanelli (P)

Department of Radiation Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Giorgia Timon (G)

Radiotherapy Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Cristiana Fodor (C)

Department of Radiation Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Giuseppe Petralia (G)

Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, Istituto Europeo di Oncologia IRCCS, via Ripamonti 435, Milan, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, via Festa del Perdono, Milan, Italy.

Sarah Alessi (S)

Department of Radiology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Paola Pricolo (P)

Department of Radiology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Barbara Vischioni (B)

Centro Nazionale di Adroterapia Oncologica, Pavia, Italy.

Piero Fossati (P)

Centro Nazionale di Adroterapia Oncologica, Pavia, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, via Festa del Perdono, Milan, Italy.

Sivia Molinelli (S)

Centro Nazionale di Adroterapia Oncologica, Pavia, Italy.

Stefania Russo (S)

Centro Nazionale di Adroterapia Oncologica, Pavia, Italy.

Mario Ciocca (M)

Centro Nazionale di Adroterapia Oncologica, Pavia, Italy.

Ottavio De Cobelli (O)

Department of Urology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, via Festa del Perdono, Milan, Italy.

Giuseppe Renne (G)

Uropathology and Intraoperative Diagnostic Division, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Roberto Orecchia (R)

Scientific Directorate, Istituto Europeo di Oncologia, IRCCS, Milan, Italy.

Federica Cattani (F)

Medical Physics Unit, Istituto Europeo di Oncologia IRCCS, Milan, Italy.

Barbara A Jereczek-Fossa (BA)

Department of Radiation Oncology, Istituto Europeo di Oncologia IRCCS, Milan, Italy.
Department of Oncology and Hemato-oncology, Università degli Studi di Milano, via Festa del Perdono, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH